Form 4: OraSure Director John Bertrand Receives Restricted Stock Grant

OraSure Technologies Director John D. Bertrand has been granted 46,106 restricted shares as part of the company's annual equity compensation plan.

Summary

• John D. Bertrand, a Director at OraSure Technologies, was granted 46,106 shares of common stock on June 3, 2026.
• The shares were issued at a price of $0.00 as part of a restricted stock grant under the OraSure Technologies, Inc. Stock Award Plan.
• Following this transaction, Bertrand's total direct ownership in the company increased to 79,767 shares.
• The restricted shares are scheduled to vest in full on the earlier of June 3, 2027, or the date of the 2027 Annual Meeting of Stockholders.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive administrative event, as it confirms continued board stability and aligns director incentives with long-term stock performance.

Positives

• Increased insider ownership by 46,106 shares, further aligning director interests with those of the shareholders.
• The grant includes a one-year vesting cliff, which incentivizes the director to remain with the board through the next annual cycle.

Negatives

• The issuance of 46,106 new shares represents a minor dilution of existing shareholder equity.

Risks

• Vesting is contingent upon continued service; if the director voluntarily leaves the board before the vesting date, the shares will be forfeited.

Future Outlook

The director is expected to remain on the board through at least June 2027 to satisfy the vesting requirements of the equity grant.

Management Comments

• Vesting shall cease immediately if the named individual voluntarily ceases to serve as a member of the Board of Directors.

Industry Context

StockSavvy.ai notes that equity-based compensation for non-employee directors is a standard industry practice in the medical diagnostics sector to ensure board members have 'skin in the game' alongside public investors.

Comparison to Industry Standards

• The one-year vesting period is consistent with standard corporate governance practices for director equity grants among NASDAQ-listed healthcare companies.
• The grant size is comparable to annual director retainers seen at peer companies such as QuidelOrtho and Meridian Bioscience.

Corporate Governance

Related Party Transactions

• The grant of 46,106 shares to Director John D. Bertrand is a compensatory transaction between the issuer and a related party.

Stakeholder Impact

• Shareholders: Experience minor dilution but benefit from a board with increased equity alignment.
• Board of Directors: John D. Bertrand increases his financial exposure to the company's performance.

Next Steps

• Vesting of the 46,106 shares on June 3, 2027, or immediately prior to the 2027 Annual Meeting of Stockholders.

Key Dates

Recommendation

This is a routine administrative filing regarding director compensation and does not signal a change in the company's fundamental business outlook or financial health.

Keywords

OraSure Technologies, OSUR, Insider Trading, Form 4, Restricted Stock, Director Compensation, John D. Bertrand, Equity Grant